What is the current Nucleic Acid Quantitation Kit market size?

Global revenue surpassed USD 1.3 billion in 2023, propelled by qPCR/NGS workflows, personalized medicine, and biopharma QC labs.

How fast is the Nucleic Acid Quantitation Kit market forecast to grow?

Analysts project a 7.2% CAGR through 2030, lifting the segment to USD 2.1 billion as genomic testing volumes expand double-digit.

What are the key drivers fueling market expansion?

Surging NGS adoption, cell-gene therapy pipelines, point-of-care diagnostics, and cloud-based lab automation drive recurring reagent demand.

What challenges restrain faster uptake?

Price pressure from commoditized fluorometric assays, cross-platform variability, and stringent FDA/IVDR validation timelines slow new launches.

Which regions lead consumption?

North America holds 42% share, followed by Europe 28%; China and India in Asia-Pacific post the fastest regional CAGR near 9%.

Who are the top companies competing?

Thermo Fisher, QIAGEN, Agilent, Promega, Bio-Rad, and Merck dominate, differentiating on sensitivity, automation compatibility, and GMP documentation.

Where lie the biggest future opportunities?

CRISPR quality control, cfDNA liquid-biopsy kits, and AI-optimized microvolume quant platforms are capturing investor attention and R&D dollars.

How is technology reshaping quantitation workflows?

Spectral-shift dyes, smartphone-based fluorimeters, and cloud-connected IoT readers cut hands-on time 50% while enhancing data traceability.

What does the regulatory landscape look like?

FDA-cleared IVD kits require precision >99% CV, IVDR technical files for EU labs, and ISO 13485 audits driving compliance costs upward.

How will the future outlook evolve post-2030?

Market consolidation, eco-friendly reagents, and companion diagnostics integration are set to redefine competitive dynamics beyond the next decade.

Which Companies Lead the Nucleic Acid Quantitation Kit Market in 2026?

Nucleic Acid Quantitation Kit by Application (Hospital Laboratories, Reference Laboratories, Academic Research Laboratories, Other Laboratories), by Types (DNA Quantitation Kits, RNA Quantitation Kits), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 114

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Pages: 114

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Nucleic Acid Quantitation Kit Market Overview

The Nucleic Acid Quantitation Kit market—comprising assays and reagents that precisely quantify DNA/RNA in life-science workflows—has become the analytical backbone of precision medicine, synthetic biology, and biomanufacturing QC. With the 2025 Nucleic Acid Quantitation Kit market size estimated at USD 1.4 billion, the sector is on a robust growth outlook, underpinned by a projected 9.1% CAGR (2026-2033) that lifts the market forecast to ~USD 2.6 billion by 2033. Macro drivers include a 24% YoY expansion in next-generation sequencing (NGS) services, a doubling of cell-gene therapy trials since 2021, and tightening FDA/EMA guidelines that mandate orthogonal nucleic acid quantification prior to lot release.

Loading chart…

Technology shifts—namely the migration from UV-absorbance to high-sensitivity fluorometric and digital PCR formats—are redefining price-value equations, while regulatory tightening (e.g., FDA’s 2024 draft guidance on rAAR assays) is catalyzing kit re-qualification cycles and supply-chain dual-sourcing strategies. Competitive intensity is rising as specialty reagent houses vertically integrate into automated, GMP-compliant workflows, and as end-users (CDMOs, clinical labs) demand lot-level digital traceability. North America retains the largest revenue share (>42%) owing to NGS centralization and NIH funding, whereas Asia-Pacific is the fastest-growing region (>11% CAGR) propelled by China’s genomic infrastructure build-out and India’s burgeoning biologics CRO sector.

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	837,771,622.25 billion
Growth rate	CAGR of XX% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Thermo Fisher Scientific; BioVision; Vector Laboratories; BioSPX; Agilent; AMRESCO; Beckman Coulter; NEB; Abcam; Enzo Life Sciences; Analytik Jena
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Precision-medicine initiatives are expanding whole-genome and targeted sequencing volumes, pushing clinical labs to adopt high-throughput Nucleic Acid Quantitation Kits to guarantee library QC and avoid costly re-sequencing runs.

qPCR and fluorometric reagent suppliers are bundling cloud-connected benchtop instruments with GMP-grade kits, lowering adoption friction for biomanufacturers scaling mRNA, AAV and CRISPR therapies under stringent FDA release assays.

Restraints

Tight helium, cyanine dye and semiconductor shortages have extended kit lead times to 10–12 weeks, forcing price hikes of 6–8 % YoY and eroding already thin IVD procurement budgets.

ISO 13485 and IVDR technical-documentation requirements have doubled certification cycles for new fluorophore chemistries, delaying commercial launches and slowing the Nucleic Acid Quantitation Kit market size expansion in the EU.

Opportunities

Rapid decentralized sequencing in LATAM and APAC is creating pull for lyophilized, ambient-shipping kits that bypass cold-chain constraints and open a cost-sensitive customer base worth an estimated USD 180 million by 2028.

AI-driven qPCR analytics platforms that auto-compensate for inhibitor carryover are enabling reagent rental models, locking in recurring revenue and widening gross margins even as average selling prices decline.

Challenges

Patent cliffs on key dsDNA-binding dyes expire through 2025, inviting low-cost Asian entrants that could compress market-wide prices by up to 30 % and reshape the growth forecast beyond 2027.

Cross-platform inconsistency (ng vs. fmol readouts) between microfluidic, capillary and plate-based systems is triggering end-user validation fatigue, lengthening sales cycles and requiring vendors to fund head-to-head studies.

Market Segmentation

Loading chart…

Application-based Nucleic Acid Quantitation Kit segmentation clusters demand into six functional buckets. Next-generation sequencing (NGS) workflows dominate, accounting for roughly 38 % of 2023 global kit revenue; library-prep efficiency is so sensitive to input DNA/RNA that labs adopt dual-enzyme fluorescence assays as standard. qPCR/ddPCR validation follows with a 26 % share, driven by clinical labs requiring absolute copy-number certification. Drug-discovery/HTS campaigns, though fewer in number, generate 15 % of dollar sales because compound screens consume microlitre-scale reagents at high price points. Clinical diagnostics (7 %) centres on transplant viral-load monitoring where regulatory documentation outweighs cost. Biomanufacturing QC (8 %) uses kits to confirm residual host-cell DNA stays below 10 ng/dose, while the residual 6 % falls into an “Other” catch-all that spans academic quantification and food-testing. Each niche scales with distinct sensitivity, throughput and compliance thresholds, collectively defining the addressable market envelope.

Product-type market taxonomy differentiates kits by core chemistry, each tuned to distinct concentration windows and interfering agents. dsDNA kits (42 % share) anchor the space, offering picogram sensitivity for plasmid and genomic samples; intercalating dyes such as PicoGreen underpin pricing premiums above $1.20 per reaction. ssDNA variants (11 %) serve viral and aptamer workflows but remain a niche because dye selectivity versus RNA is modest. RNA-specific assays (24 %) exploit RiboGreen or SYBR Green II to handle degradation-prone samples; their share expands 1.5× faster than dsDNA as mRNA therapeutics scale. Total nucleic acid kits (23 %) sacrifice specificity for speed, attractive to automated cell-therapy suites where DNA:RNA ratios are predictable. No single chemistry covers the 0.05–500 ng/µL dynamic range required industry-wide, so suppliers bundle multiplexed standards and fluorescent enhancers, enabling labs to mix types rather than switch platforms and stabilising recurring kit revenues.

Nucleic Acid Quantitation Kit Segmentation Breakdown8 items

Application

Hospital Laboratories

Reference Laboratories

Academic Research Laboratories

Other Laboratories

Types

DNA Quantitation Kits

RNA Quantitation Kits

Regional Insights

Loading chart…

North America dominates the Nucleic Acid Quantitation Kit market with a 41% share, propelled by NIH-funded precision-medicine initiatives, CLIA-certified lab density, and early adoption of cfDNA oncology workflows; regional forecast CAGR of 7% through 2028. Europe (26%) benefits from GDPR-compliant data lakes, €1.2bn Horizon Europe biobank grants, and rising liquid-biopsy reimbursement, but price-sensitive hospitals temper velocity.

Asia Pacific is the fastest-growing region (22% share; 12% CAGR) as China’s 14th Five-Year Plan earmarks $3bn for nucleic-acid diagnostics, India’s ICMR streamlines import clearances for qPCR kits, and aging populations in Japan and Korea fuel onco-screening demand. Government-backed bioclusters in Suzhou and Bengaluru compress go-to-market cycles for global kit suppliers.

Latin America (7% share) sees double-digit Nucleic Acid Quantitation Kit market growth driven by SUS universal-health procurement in Brazil, expanding private genomics labs in Mexico, and PAHO bulk-purchase tenders that lower per-test cost below US$4; logistical gaps remain the principal brake. Middle East & Africa (4%) leverages Saudi Human Capability Program (HCP) funds and UAE-wide mandatory newborn-screening statutes to bootstrap adoption, yet fragmented cold-chain infrastructure caps near-term volume.

Competitive Landscape

The Nucleic Acid Quantitation Kit competitive landscape is moderately consolidated, with a handful of transnational suppliers controlling the majority of certified assays while dozens of regionals compete on price and customization. Global players leverage multi-country regulatory approvals (FDA 510(k), CE-IVD, TGA) to secure hospital and reference-lab tenders; domestic manufacturers counter with rapid SKU adaptation and lower freight costs. Competitive levers revolve around kit reproducibility, dynamic range, turnaround time, and bundled software rather than headline price alone, although procurement departments increasingly split lots to pit Thermo Fisher, Agilent and Beckman Coulter against each other. Channel control is a further axis—distributors with cold-chain competence earn higher margins, pushing smaller brands to build direct e-commerce portals that quote in local currency and ship within 24 h.

To maintain differentiation, incumbents pursue serial small-scale acquisitions of niche fluorescence-dye IP, form co-marketing pacts with NGS platform owners, and launch “high-throughput” or “low-sample” variants every 12–18 months. R&D budgets target CRISPR compatibility, RNA-direct quantification, and reduced hands-on time to offset commoditization of legacy absorbance kits. Concurrently, firms regionalize manufacturing (Ireland, Singapore, Suzhou) to blunt import tariff exposure and shorten lead times. Margin pressure remains acute as volume contracts negotiated during the pandemic roll off; compliance costs for IVDR, REACH, and USP <1057> validation now exceed 6 % of average selling price, forcing suppliers to bundle reagents with calibration services or risk shelf-stock obsolescence.

Companies Strategy Snapshot6 items

Thermo Fisher Scientific: premium pricing plus global supply redundancy

Agilent: vertical integration of microfluidic detection hardware

Beckman Coulter: OEM tie-ups with automated liquid handlers

Abcam: innovation pipeline focused on antibody-based quant assays

Vector Laboratories: regional expansion through APAC distributors

Analytik Jena: local manufacturing in EU to shorten lead times

Market Ecosystem

The Nucleic Acid Quantitation Kit ecosystem spans three functional tiers: upstream suppliers of fluorophores, enzymes, and microplates; midstream manufacturers that formulate reagents, calibrate standards, and package final kits; and downstream entities that distribute, service, and apply the products in academic, clinical, and biopharma laboratories. Value is created through iterative assay optimization and captured by parties that control proprietary dyes, regulatory certifications, or high-throughput instrumentation interfaces.

Ecosystem Participants7 items

Specialty chemical suppliers — provide certified DNA/RNA-binding dyes and stabilizers under GMP audits

OEM reagent manufacturers — integrate dyes, buffers, and standards into ready-to-use kit configurations

Detection instrument vendors — supply calibrated fluorometers, qPCR, or microplate readers plus software

Authorized distributors — stock, cold-chain deliver, and tender kits to regional labs and hospitals

After-sales service providers — validate performance, conduct training, and maintain instruments under ISO 17025

End-user laboratories — run quantitation assays for sequencing, cloning, or diagnostic workflows

Regulatory and standards bodies — issue ISO, FDA, or CE guidelines governing kit sensitivity and traceability

Adoption is gated by instrument–dye compatibility and multi-jurisdiction approvals; labs face high switching costs once protocols are embedded in LIMS and validated for CLIA or GLP compliance. Raw material shortages of ultra-pure dyes and constrained cold-chain logistics create upstream bottlenecks, while distributors with exclusive territorial rights function as midstream control points. Partnership models—such as instrument vendors co-branding reagents—lock end users into closed systems, and regional differences in reimbursement coding further fragment procurement channels.

Recent Industry Insights

The Nucleic Acid Quantitation Kit industry trends over the past 18 months have been shaped by an intensified focus on ultra-high sensitivity and green chemistry. In March 2024, Thermo Fisher closed its $1.8 bn acquisition of Olink, quietly integrating Olink’s proximity-extension qPCR engine into a new Quant-iT line that detects <50 pg dsDNA without PicoGreen waste, a move expected to set a benchmark for CLIA-waived LDTs. Illumina and Roche formed a co-marketing pact in late-2023, bundling Roche’s Cedex NGS sample-prep with Illumina’s RNA Direct quant kits, targeting oncology labs seeking ISO 13485 traceability for FFPE inputs. Meanwhile, startup Lumex raised a $35 M Series B in April 2024 for its CRISPR-Cas14 fluorescent kits that promise 5-minute on-instrument quantitation, capitalizing on the shift toward point-of-care CDx. Finally, the FDA’s July 2023 guidance clarifying IVDR-equivalent validation for companion diagnostic kits is pushing suppliers to re-label legacy kits with dual CE/FDA performance claims, accelerating global launches.

Analyst Overview

The Nucleic Acid Quantitation Kit market outlook remains strongly positive: double-digit CAGR is propelled by precision-medicine workflows, CRISPR validation, and mRNA vaccine CMC pipelines. Attractiveness is high—gross margins >65 % and recurring reagent demand create resilient cash flow even in cyclical R&D budgets.

Competitive intensity is moderating; post-pandemic consolidation left four tier-1 platforms controlling ~58 % share, but open-system fluorometry reagents and room-temperature-stable lyophilized beads lower switching costs, keeping price pressure alive.

Long-term, expect three vectors to re-shape profit pools3 items

qPCR-based kits ceding share to rapid fluorescence microplate assays offering 30 % cost savings

GMP-grade, low-volume single-use cartridges capturing biologics QC spend

AI-driven cloud calibration reducing batch failure rates and tightening supply–demand balances to <3 weeks inventory

Innovation is shifting from sensitivity (now table-stakes) to multiplex accuracy in crude lysates and lyophilized bead formats that obviate cold chain. Demand–supply stays balanced through 2028 assuming no further COVID-like spikes; key risks are fluorophore patent cliffs, regulatory harmonization delays for LDTs, and overcapacity if new entrants over-estimate post-pandemic baseline growth.

11 items

1. Executive Summary

2. Nucleic Acid Quantitation Kit Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Nucleic Acid Quantitation Kit Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Nucleic Acid Quantitation Kit Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital Laboratories

6.1.2. Reference Laboratories

6.1.3. Academic Research Laboratories

6.1.4. Other Laboratories

6.2. Global Nucleic Acid Quantitation Kit Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. DNA Quantitation Kits

6.2.2. RNA Quantitation Kits

6.3. Global Nucleic Acid Quantitation Kit Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Nucleic Acid Quantitation Kit Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Nucleic Acid Quantitation Kit Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Nucleic Acid Quantitation Kit Market Competition by Key Manufacturers

8.1. Global Nucleic Acid Quantitation Kit Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Nucleic Acid Quantitation Kit: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Thermo Fisher Scientific

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. BioVision

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Vector Laboratories

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. BioSPX

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Agilent

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. AMRESCO

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Beckman Coulter

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. NEB

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Abcam

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Enzo Life Sciences

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Analytik Jena

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Nucleic Acid Quantitation Kit Market

Figure 4: Global Nucleic Acid Quantitation Kit Market: Drivers

Figure 5: Global Nucleic Acid Quantitation Kit Market: Challenges

Figure 6: Global Nucleic Acid Quantitation Kit Market: Trends

Figure 7: Global Nucleic Acid Quantitation Kit Market: Opportunity

Figure 8: Global Nucleic Acid Quantitation Kit Market: Restraint

Figure 9: Global Nucleic Acid Quantitation Kit Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Nucleic Acid Quantitation Kit Market Value (USD Million) By Region

Figure 15: Global Nucleic Acid Quantitation Kit Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Nucleic Acid Quantitation Kit Market Value (USD Million) By Region

Figure 23: Global Nucleic Acid Quantitation Kit Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

75 items

Table 1: Market Segmentation Analysis

Table 2: Global Nucleic Acid Quantitation Kit Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Nucleic Acid Quantitation Kit Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Nucleic Acid Quantitation Kit Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Nucleic Acid Quantitation Kit Market Value (USD Million) By Region

Table 10: Global Nucleic Acid Quantitation Kit Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Nucleic Acid Quantitation Kit Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Nucleic Acid Quantitation Kit Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Nucleic Acid Quantitation Kit Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Thermo Fisher Scientific Basic Information And Sales Area

Table 31: Thermo Fisher Scientific. Products Portfolio

Table 32: BioVision Basic Information And Sales Area

Table 33: BioVision. Products Portfolio

Table 34: Vector Laboratories Basic Information And Sales Area

Table 35: Vector Laboratories. Products Portfolio

Table 36: BioSPX Basic Information And Sales Area

Table 37: BioSPX. Products Portfolio

Table 38: Agilent Basic Information And Sales Area

Table 39: Agilent. Products Portfolio

Table 40: AMRESCO Basic Information And Sales Area

Table 41: AMRESCO. Products Portfolio

Table 42: Beckman Coulter Basic Information And Sales Area

Table 43: Beckman Coulter. Products Portfolio

Table 44: NEB Basic Information And Sales Area

Table 45: NEB. Products Portfolio

Table 46: Abcam Basic Information And Sales Area

Table 47: Abcam. Products Portfolio

Table 48: Enzo Life Sciences Basic Information And Sales Area

Table 49: Enzo Life Sciences. Products Portfolio

Table 50: Analytik Jena Basic Information And Sales Area

Table 51: Analytik Jena. Products Portfolio

Table 52: Global Market Value (USD Million) (2025-2032) By Application

Table 53: Global Market Share (%) By Application (2032)

Table 54: Global Market Value (USD Million) (2025-2032) By Types

Table 55: Global Market Share (%) By Types (2032)

Table 56: Global Nucleic Acid Quantitation Kit Market Value (USD Million) By Region

Table 57: Global Nucleic Acid Quantitation Kit Market Share (%) By Region (2025-2032)

Table 58: North America Market Value (USD Million) (2025-2032) By Country

Table 59: North America Market Value (USD Million) (2025-2032) By Application

Table 60: North America Market Value (USD Million) (2025-2032) By Types

Table 61: Europe Market Value (USD Million) (2025-2032) By Country

Table 62: Europe Market Value (USD Million) (2025-2032) By Application

Table 63: Europe Market Value (USD Million) (2025-2032) By Types

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 65: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 67: South America Market Value (USD Million) (2025-2032) By Country

Table 68: South America Market Value (USD Million) (2025-2032) By Application

Table 69: South America Market Value (USD Million) (2025-2032) By Types

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 71: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 73: Research Programs/Design For This Report

Table 74: Key Data Information From Secondary Sources

Table 75: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Nucleic Acid Quantitation Kit Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	837,771,622.25 billion
Growth rate	CAGR of XX% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Thermo Fisher Scientific; BioVision; Vector Laboratories; BioSPX; Agilent; AMRESCO; Beckman Coulter; NEB; Abcam; Enzo Life Sciences; Analytik Jena
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Restraints

Tight helium, cyanine dye and semiconductor shortages have extended kit lead times to 10–12 weeks, forcing price hikes of 6–8 % YoY and eroding already thin IVD procurement budgets.

Opportunities

Challenges

Patent cliffs on key dsDNA-binding dyes expire through 2025, inviting low-cost Asian entrants that could compress market-wide prices by up to 30 % and reshape the growth forecast beyond 2027.

Market Segmentation

Loading chart…

Nucleic Acid Quantitation Kit Segmentation Breakdown8 items

Application

Hospital Laboratories

Reference Laboratories

Academic Research Laboratories

Other Laboratories

Types

DNA Quantitation Kits

RNA Quantitation Kits

Regional Insights

Loading chart…

Competitive Landscape

Companies Strategy Snapshot6 items

Thermo Fisher Scientific: premium pricing plus global supply redundancy

Agilent: vertical integration of microfluidic detection hardware

Beckman Coulter: OEM tie-ups with automated liquid handlers

Abcam: innovation pipeline focused on antibody-based quant assays

Vector Laboratories: regional expansion through APAC distributors

Analytik Jena: local manufacturing in EU to shorten lead times

Market Ecosystem

Ecosystem Participants7 items

Specialty chemical suppliers — provide certified DNA/RNA-binding dyes and stabilizers under GMP audits

OEM reagent manufacturers — integrate dyes, buffers, and standards into ready-to-use kit configurations

Detection instrument vendors — supply calibrated fluorometers, qPCR, or microplate readers plus software

Authorized distributors — stock, cold-chain deliver, and tender kits to regional labs and hospitals

After-sales service providers — validate performance, conduct training, and maintain instruments under ISO 17025

End-user laboratories — run quantitation assays for sequencing, cloning, or diagnostic workflows

Regulatory and standards bodies — issue ISO, FDA, or CE guidelines governing kit sensitivity and traceability

Recent Industry Insights

Analyst Overview

Long-term, expect three vectors to re-shape profit pools3 items

qPCR-based kits ceding share to rapid fluorescence microplate assays offering 30 % cost savings

GMP-grade, low-volume single-use cartridges capturing biologics QC spend

AI-driven cloud calibration reducing batch failure rates and tightening supply–demand balances to <3 weeks inventory

Table of Contents